Coronavirus Disease 2019 (COVID-19) and Inflammatory Bowel Disease

The COVID-19 pandemic created many challenges and uncertainty in our healthcare system. One component facing clinicians managing patients with inflammatory bowel disease (IBD) is whether or not to continue providing certain pharmacotherapies in patients who are at increased risk of infection because they are immunocompromised. The consensus of gastroenterologists is that decisions should be made on a case-by-case basis, but that overall, uncontrolled disease activity and inflammation present more harm to individual patients than remaining on their biologic therapy.

Dr. Rubin, Dr. Regueiro, and Dr. Dalal have been on the frontlines of the pandemic and have been leaders in guiding care for patients with IBD based on current evidence and experience. This CMEOCast podcast is a featured excerpt from the broader virtual symposium Ulcerative Colitis in the 21st Century: Incorporating Guidelines and Real-World Evidence in Practice to Enhance Patient-Centered Care presented to assist health care providers in optimizing the management of patients with IBD during the COVID-19 pandemic.

- Learning Objectives -

At the end of this CE activity, participants should be able to:
- Apply expert recommendations for the management of IBD during the COVID-19 pandemic.